“We need future studies to help us understand the relationship between cholesterol variability and dementia risk,” she said ...

Innovative urinary miRNA profiling shows potential for early pancreatic cancer detection, with high accuracy and sensitivity, ...

VacSYn is an adaptive, placebo-controlled, and biomarker-based Phase 2 study in patients with early PD, consisting of two ...

Q3 2024 Earnings Call Transcript November 13, 2024 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS ...

suggesting the accumulation of antibodies as an aging hallmark and the potential of IgG as a biomarker of aging. In human and ...

It's the third prize sponsored by the Richard King Mellon Foundation. A team studying a link between obesity and high-risk ...

The survey also identified opportunities for more comprehensive patient support, such as greater understanding of biomarker testing to inform treatment and emotional health resources. This survey ...

In the oral presentation, the investigators reported ongoing improved survival compared to historical controls, with 3 out of ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three ...

ADAP READ THE FULL ADAP RESEARCH REPORT Post-market close on 11/13/24, Adaptimmune (NASDAQ:ADAP) reported 3Q24 earnings results. ADAP reported a net loss of $17.6 million for 3Q24, or $(0.01) per ...

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how ...

VacSYn is an adaptive, placebo-controlled, and biomarker-based Phase 2 study in patients with early PD, consisting of two parts with a seamless transition. Part 1 includes initial analyses from over ...